Listen in as Katie Sale, American Brain Coalition's Executive Director, has a conversation with Frank Amato, Chief Executive Officer and President of SYNAPS Dx Biomarker Technology to learn more about their organization's history and DISCERN™ the world’s first easy-to-administer test that can accurately identify Alzheimer’s Disease even at the earliest stages of onset by testing for the presence of 3 key proprietary biomarkers, unique to AD.
